PACB

Pacific Biosciences of California, Inc. [PACB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PACB Stock Summary

Top 10 Correlated ETFs

PACB


Top 10 Correlated Stocks

PACB


In the News

11:21 29 Mar 2024 PACB

PacBio's (PACB) New Panel to Aid Its Clinical Research Solution

PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.

11:51 29 Mar 2024 PACB

PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down

PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.

07:31 29 Mar 2024 PACB

Pacific Biosciences (PACB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

06:39 29 Mar 2024 PACB

Pacific Biosciences of California, Inc. (PACB) Q4 2023 Earnings Call Transcript

Pacific Biosciences of California, Inc. (PACB) Q4 2023 Earnings Call Transcript

06:31 29 Mar 2024 PACB

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.35 per share a year ago.

01:59 29 Mar 2024 PACB

7 Stocks Cathie Wood Is Still Loading Up On in Q1

You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.

10:47 29 Mar 2024 PACB

PacBio's (PACB) New Kits to Boost Its Revio Sequencing System

PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.

01:32 29 Mar 2024 PACB

PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction

PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.

12:02 29 Mar 2024 PACB

PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

04:05 29 Mar 2024 PACB

PacBio to Present at 42nd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif. , Dec. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 42nd Annual J.P.

PACB Financial details

Company Rating
Buy
Market Cap
986.06M
Income
-299.87M
Revenue
200.52M
Book val./share
2.63
Cash/share
2.36
Dividend
-
Dividend %
-
Employees
796
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
-6.58
Forward P/E
-4.35
PEG
6.68
P/S
12.12
P/B
2.56
P/C
1.59
P/FCF
-9.87
Quick Ratio
10.21
Current Ratio
11.31
Debt / Equity
1.29
LT Debt / Equity
1.27
-
-
EPS (TTM)
-1.19
EPS next Y
-0.86
EPS next Q
-0.26
EPS this Y
-8.33%
EPS next Y
-27.83%
EPS next 5Y
-90.76%
EPS last 5Y
18.86%
Revenue last 5Y
17.15%
Revenue Q/Q
4.79%
EPS Q/Q
19.23%
-
-
-
-
SMA20
-20%
SMA50
-42.86%
SMA100
-42.86%
Inst Own
81.81%
Inst Trans
0.79%
ROA
-16%
ROE
-45%
ROC
-0.18%
Gross Margin
29%
Oper. Margin
-194%
Profit Margin
-176%
Payout
-
Shs Outstand
267.95M
Shs Float
252M
-
-
-
-
Target Price
10.75
52W Range
3.54-14.55
52W High
-73.25%
52W Low
+24.83%
RSI
36
Rel Volume
0.62
Avg Volume
8.64M
Volume
5.39M
Perf Week
-1.96%
Perf Month
-43.85%
Perf Quarter
-53.94%
Perf Half Y
-55.73%
-
-
-
-
Beta
1.866
-
-
Volatility
0.09%, 0.72%
Prev Close
0.67%
Price
3.745
Change
4.03%

PACB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.60.460.640.570.79
Net income per share
-0.510.17-0.89-1.32-1.21
Operating cash flow per share
-0.510.11-0.55-1.17-1.05
Free cash flow per share
-0.530.11-0.58-1.25-1.09
Cash per share
0.453.215.133.442.49
Book value per share
0.361.943.882.512.77
Tangible book value per share
0.361.94-0.15-1.15-0.86
Share holders equity per share
0.361.943.882.512.77
Interest debt per share
0.550.274.784.333.61
Market cap
783.99M4.49B4.17B1.84B2.49B
Enterprise value
796.56M4.21B4.66B2.47B3.24B
P/E ratio
-10.07152.59-22.99-6.18-8.11
Price to sales ratio
8.6356.8731.9214.3112.41
POCF ratio
-10.01230.04-37.47-6.98-9.33
PFCF ratio
-9.66242.99-35.57-6.55-9.03
P/B Ratio
14.2813.375.273.263.55
PTB ratio
14.2813.375.273.263.55
EV to sales
8.7653.3635.719.2416.17
Enterprise value over EBITDA
-8-41.14-26.16-8.31-11.67
EV to operating cash flow
-10.17215.85-41.91-9.38-12.16
EV to free cash flow
-9.82228-39.78-8.81-11.77
Earnings yield
-0.10.01-0.04-0.16-0.12
Free cash flow yield
-0.10-0.03-0.15-0.11
Debt to equity
1.480.141.221.71.29
Debt to assets
0.550.110.480.540.52
Net debt to EBITDA
-0.132.71-2.77-2.13-2.71
Current ratio
3.719.7213.2811.127.81
Interest coverage
-38.51-390.96-14.22-20.75-21.64
Income quality
0.930.660.610.840.87
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.660.810.871.50.93
Intangibles to total assets
000.410.460.53
Capex to operating cash flow
0.04-0.050.050.060.03
Capex to revenue
-0.03-0.01-0.05-0.13-0.04
Capex to depreciation
-0.29-0.11-0.51-0.98-0.27
Stock based compensation to revenue
0.180.220.560.610.36
Graham number
2.032.728.828.648.67
ROIC
-0.51-0.3-0.06-0.18-0.18
Return on tangible assets
-0.530.07-0.15-0.31-0.37
Graham Net
-0.042.88-0.69-1.75-1.41
Working capital
59.21M318.26M1.02B778.08M647.02M
Tangible asset value
54.92M335.49M-29.97M-257.32M-217.94M
Net current asset value
-12.02M276.26M-110.26M-349.19M-302.66M
Invested capital
1.480.141.221.71.29
Average receivables
11.93M16.05M20.54M21.51M27.7M
Average payables
7.55M5.97M7.29M11.52M13.55M
Average inventory
15.6M13.77M19.41M37.49M53.53M
Days sales outstanding
61.3177.967.7953.4466.65
Days payables outstanding
54.2428.256.0455.3834.32
Days of inventory on hand
86.28112.11125.31231.98129.15
Receivables turnover
5.954.695.386.835.48
Payables turnover
6.7312.946.516.5910.63
Inventory turnover
4.233.262.911.572.83
ROE
-1.420.09-0.23-0.53-0.44
Capex per share
-0.02-0.01-0.03-0.08-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.120.160.190.220.22
Net income per share
-0.35-0.34-0.28-0.26-0.31
Operating cash flow per share
-0.27-0.39-0.17-0.26-0.22
Free cash flow per share
-0.29-0.41-0.18-0.26-0.22
Cash per share
3.413.613.333.012.36
Book value per share
2.492.862.5732.63
Tangible book value per share
-1.14-0.53-0.71-0.64-0.82
Share holders equity per share
2.492.862.5732.63
Interest debt per share
4.253.963.813.723.39
Market cap
1.85B2.8B3.32B2.13B2.62B
Enterprise value
2.48B3.39B4.05B3.11B3.37B
P/E ratio
-5.79-8.63-11.87-7.96-7.99
Price to sales ratio
67.6672.0569.7338.2344.9
POCF ratio
-30.56-29.6-79.47-32.67-45.49
PFCF ratio
-28.19-28.48-75.37-32.26-43.94
P/B Ratio
3.294.055.172.793.74
PTB ratio
3.294.055.172.793.74
EV to sales
90.7787.2485.0455.8157.82
Enterprise value over EBITDA
-32.61-47.05-64.96-48.16-39.06
EV to operating cash flow
-41-35.84-96.92-47.69-58.57
EV to free cash flow
-37.82-34.48-91.92-47.09-56.58
Earnings yield
-0.04-0.03-0.02-0.03-0.03
Free cash flow yield
-0.04-0.04-0.01-0.03-0.02
Debt to equity
1.71.381.471.241.29
Debt to assets
0.540.50.510.50.52
Net debt to EBITDA
-8.3-8.19-11.7-15.17-8.73
Current ratio
11.1214.1612.7611.317.81
Interest coverage
-22.61-25.14-20.59-22.99-24.19
Income quality
0.721.080.60.970.7
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
1.561.260.970.850.76
Intangibles to total assets
0.460.430.440.490.53
Capex to operating cash flow
0.080.040.050.010.04
Capex to revenue
-0.19-0.1-0.05-0.01-0.03
Capex to depreciation
-1.12-0.82-0.47-0.15-0.11
Stock based compensation to revenue
0.660.460.380.350.28
Graham number
4.444.644.034.24.26
ROIC
-0.05-0.05-0.05-0.04-0.05
Return on tangible assets
-0.08-0.08-0.07-0.07-0.1
Graham Net
-1.74-1.14-1.3-1.22-1.34
Working capital
778.08M914.55M864.48M806.53M647.02M
Tangible asset value
-257.32M-127.87M-177.75M-161.94M-217.94M
Net current asset value
-349.19M-220.27M-267.66M-249.89M-302.66M
Invested capital
1.71.381.471.241.29
Average receivables
20.77M24.19M26.81M27.26M33.55M
Average payables
12.44M14.71M16.95M16.31M15.58M
Average inventory
46.94M56.17M64.78M67.93M62.47M
Days sales outstanding
61.8168.4645.4749.2756.47
Days payables outstanding
48.7353.7146.438.3628.63
Days of inventory on hand
204.13191.36189.99162.56107.72
Receivables turnover
1.461.311.981.831.59
Payables turnover
1.851.681.942.353.14
Inventory turnover
0.440.470.470.550.84
ROE
-0.14-0.12-0.11-0.09-0.12
Capex per share
-0.02-0.02-0.010-0.01

PACB Frequently Asked Questions

What is Pacific Biosciences of California, Inc. stock symbol ?

Pacific Biosciences of California, Inc. is a US stock , located in Menlo park of Ca and trading under the symbol PACB

Is Pacific Biosciences of California, Inc. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $11.88. The lowest prediction is $6 and the highest is $20

What is PACB stock prediction ?

What is Pacific Biosciences of California, Inc. stock quote today ?

Pacific Biosciences of California, Inc. stock price is $3.745 today.

Is Pacific Biosciences of California, Inc. stock public?

Yes, Pacific Biosciences of California, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap